Journal
Nature Communications
Publication Date
2017
Volume
8
Document Type
Open Access Publication
DOI
10.1038/ncomms14060
Rights and Permissions
Shirai, C. L. et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat. Commun. 8, 14060 doi: 10.1038/ncomms14060 (2017). This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Copyright The Author(s) 2017
Recommended Citation
Shirai, Cara Lunn; White, Brian S.; Tripathi, Manorama; Tapia, Roberto; Ley, James N.; Ndonwi, Matthew; Kim, Sanghyun; Shao, Jin; Carver, Alexa; Saez, Borja; Fulton, Robert S.; Fronick, Catrina; O’Laughlin, Michelle; Lagisetti, Chandraiah; Webb, Thomas R.; Graubert, Timothy A.; and Walter, Matthew J., "Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome." Nature Communications. 8, (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5563
Supplementary Figures, Supplementary Methods and Supplementary References
Supplementary Data 1.xlsx (281 kB)
Genes differentially expressed (DESeq, FDR<5%, |log2FC>1|) in primary human CD34+ hematopoietic cells treated with Sudemycin D6.
Supplementary Data 2.xlsx (2116 kB)
Differentially spliced junctions (FDR<5%, |delta percent spliced in or PSI (Δψ)|>10%) in primary human CD34+ hematopoietic cells treated with Sudemycin D6.
Supplementary Data 3.xlsx (26 kB)
Pathways enriched (GOseq FDR < 0.1) in differentially spliced genes in primary human CD34+ hematopoietic cells following treatment with sudemycin D6.
Supplementary Data 4.xlsx (13 kB)
Pathways enriched (GOseq FDR < 0.1) in differentially expressed genes in primary human CD34+ hematopoietic cells following treatment with sudemycin D6.
Supplementary Data 5.xlsx (460 kB)
Differentially spliced junctions (FDR<10%, |delta percent spliced in or PSI (Δψ)|>1%) between vehicle-treated mutant and wildtype U2AF1-expressing bone marrow cells in vivo.
Supplementary Data 6.xlsx (235 kB)
Differentially spliced junctions (FDR<10%, |delta percent spliced in or PSI (Δψ)|>1%) between vehicle-treated and sudemycin D6-treated wildtype U2AF1-expressing bone marrow cells in vivo.
Supplementary Data 7.xlsx (102 kB)
Differentially spliced junctions (FDR<10%, |delta percent spliced in or PSI (Δψ)|>1%) between vehicle-treated and sudemycin D6-treated mutant U2AF1-expressing bone marrow cells in vivo.
Supplementary Data 8.xlsx (513 kB)
Differentially spliced junctions (FDR<10%, |delta percent spliced in or PSI (Δψ)|>1%) between sudemycin-treated mutant and wildtype U2AF1-expressing bone marrow cells in vivo.
Supplementary Data 9.xlsx (476 kB)
Differentially spliced junctions (FDR<10%, |delta percent spliced in or PSI (Δψ)|>1%) between vehicle-treated wildtype U2AF1- and sudemycin D6-treated mutant U2AF1-expressing bone marrow cells in vivo.
Supplementary Data 10.xlsx (374 kB)
List of "high confidence" splice junctions that are differentially spliced by mutant U2AF1(S34F) in mouse bone marrow cells.
Supplementary Data 11.xlsx (84 kB)
List of "high confidence" splice junctions that are differentially spliced by sudemycin D6 in mouse bone marrow cells.
Supplementary Data 12.xlsx (5183 kB)
Genes differentially expressed between vehicle-treated and drug-treated wildtype U2AF1- and mutant U2AF1-expressing bone marrow cells (FDR<10%) in vivo.
Supplementary Data 13.xlsx (56 kB)
Pathways enriched (GOseq FDR < 0.1) in genes differentially expressed between vehicle-treated and drug-treated wildtype U2AF1- and mutant U2AF1-expressing bone marrow cells in vivo.
